Acadia Pharma (ACAD) Tops Q1 EPS by 5c, Misses on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Broadcom rises 3% on OpenAI custom "Jalapeño" chip reveal
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Acadia Pharmaceuticals (ACAD) PT Lowered to $22 at BofA Securities
May 10, 2024 5:24 AM EDTBofA Securities analyst Tazeen Ahmad lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $22.00 (from $26.00) while maintaining a Neutral rating.
The analyst comments "ACAD reported 1Q24 Daybue revenues of $75.9mn slightly missing their 1Q guidance of $76-82mn. Mgmt attributed the 1Q... More
